Busulfan and metronidazole: An often forgotten but significant drug interaction

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages

  Gulbis, Alison M ^a   Culotta, Kirk S ^a   Jones, Roy B ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Busulfan; Drug interactions; Metronidazole

Indexed keywords

BUSULFAN; CLOFARABINE; CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE A1; LORAZEPAM; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THIOTEPA; ALKYLATING AGENT; ANTIINFECTIVE AGENT; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CASE REPORT; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE COURSE; DRUG MONITORING; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD; BLOOD; CLOSTRIDIUM DIFFICILE; DRUG EFFECT; DRUG INTERACTION; HALF LIFE TIME; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; METABOLIC CLEARANCE RATE; PSEUDOMEMBRANOUS COLITIS;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CLOSTRIDIUM DIFFICILE; DRUG INTERACTIONS; DRUG MONITORING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HALF-LIFE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLIC CLEARANCE RATE; METRONIDAZOLE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING;

EID: 79960791738     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q087     Document Type: Article

References (16)

1. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-30560.
2. Dix S P, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-230.
3. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-485.
4. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacoki-netics of intravenous busulfan when used with oral busulfan and cy-clophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000;6:548-554.
5. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13:56-64. DOI 10.1016/j.bbmt.2006.08.037
6. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Goodman LS, Gilman A, Limbird LE, Hardman JG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996:1241-2.
7. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999;27:1466-1469.
8. Nilsson C, Aschan J, Hentschke P, Ringden O, Ljungman P, Hassan M. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:429-435. DOI 10.1038/sj.bmt.1703896
9. Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother 2007;41:653-658. DOI 10.1345/aph.1H401
10. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isoenzymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002;49:461-467. DOI 10.1007/s00280-002-0453-3
11. Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophospho-ramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002;30:525-530. DOI 10.1124/dmd.30.5.525
12. Tran H, Petropoulos D, Worth L, et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004;10:805-812. DOI 10.1016/j.bbmt.2004.07.010
13. Copelan EA, Bechtel TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001;27:1121-1124.
14. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of phar-macokinetic and pharmacodynamic profile with therapeutic drug monitoring. Transplantation 2010;115:4597-4604. DOI 10.1182/blood-2010-01-265405
15. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinet-ics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001;29:264-267.
16. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-680. DOI 10.1345/aph.1H423